Evaluation of metabolite levels through relative peak areas demonstrated that the mean GPC/PCho ratio was significantly higher in triple negative breast cancer than in ER+/PgR+ breast cancer. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.